Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain.

Trial Profile

Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Clobazam (Primary) ; Imipramine (Primary) ; Oxycodone (Primary) ; Tolterodine (Primary)
  • Indications Back pain
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms Predictio
  • Most Recent Events

    • 05 Apr 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 27 Dec 2012 Planned End Date changed from 1 Jul 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 28 Aug 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top